Startup to trial drug to prevent cancer therapy side-effect 'cytokine storm'

A London startup, Poolbeg Pharma, is set to trial a drug aimed at preventing "cytokine storm," a dangerous side-effect of certain cancer therapies. The drug targets an overreaction of the immune system triggered by treatments like CAR-T cell therapy. The clinical trial will test its effectiveness in cancer patients.